The European Centre for Disease Prevention and Control (ECDC) on Thursday 5 January published an assessment of the XBB.1.5 sub-variant of interest of SARS-CoV-2.
This recombinant variant is attached to the XBB sub-lineage and has a mutation in the spike protein: S486P.
ECDC currently believes that it has a significant growth advantage over lines circulating previously in Europe and North America due, presumably, to its potential for vaccine escape from XBB combined with a higher potential...